Prostein expression in human tumors: a tissue microarray study on 19,202 tumors from 152 different Tumor entities.

Human cancers Immunohistochemistry Prostein Tissue microarray

Journal

Diagnostic pathology

ISSN: 1746-1596

Titre abrégé: Diagn Pathol

Pays: England

ID NLM: 101251558

Informations de publication

Date de publication:
13 Jan 2024

Historique:

received: 03 11 2023

accepted: 21 12 2023

medline: 14 1 2024

pubmed: 14 1 2024

entrez: 13 1 2024

Statut: epublish

Résumé

Prostein (P501S), also termed solute carrier family 45 member 3 (SLC45A3) is an androgen regulated protein which is preferentially expressed in prostate epithelial cells. Because of its frequent expression in prostate cancer, prostein was suggested a diagnostic prostate cancer marker. In order to comprehensively assess the diagnostic utility of prostein immunohistochemistry, a tissue microarray containing 19,202 samples from 152 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Prostein immunostaining was typically cytoplasmic, granular and perinuclear. Prostein positivity was seen in 96.7% of 419 prostate cancers including 78.3% with strong staining. In 16,709 extra-prostatic tumors, prostein positivity was observed in 7.2% of all cases but only 0.3% had a strong staining. Overall, 50 different extra-prostatic tumor categories were prostein positive, 12 of which included at least one strongly positive case. Extra-prostatic tumors with highest rates of prostein positivity included different subtypes of salivary gland tumors (7.6-44.4%), neuroendocrine neoplasms (15.8-44.4%), adenocarcinomas of the gastrointestinal tract (7.3-14.8%), biliopancreatic adenocarcinomas (3.6-38.7%), hepatocellular carcinomas (8.1%), and adenocarcinomas of other organs (up to 21%). Our data provide a comprehensive overview on prostein expression in human cancers. Prostein is a highly sensitive prostate cancer marker occurring in > 96% of prostate cancers. Because prostein can also be expressed in various other tumor entities, classifying of a tumor mass as a prostate cancer should not be based on prostein positivity alone.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

In order to comprehensively assess the diagnostic utility of prostein immunohistochemistry, a tissue microarray containing 19,202 samples from 152 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry.

RESULTS RESULTS

Prostein immunostaining was typically cytoplasmic, granular and perinuclear. Prostein positivity was seen in 96.7% of 419 prostate cancers including 78.3% with strong staining. In 16,709 extra-prostatic tumors, prostein positivity was observed in 7.2% of all cases but only 0.3% had a strong staining. Overall, 50 different extra-prostatic tumor categories were prostein positive, 12 of which included at least one strongly positive case. Extra-prostatic tumors with highest rates of prostein positivity included different subtypes of salivary gland tumors (7.6-44.4%), neuroendocrine neoplasms (15.8-44.4%), adenocarcinomas of the gastrointestinal tract (7.3-14.8%), biliopancreatic adenocarcinomas (3.6-38.7%), hepatocellular carcinomas (8.1%), and adenocarcinomas of other organs (up to 21%).

CONCLUSIONS CONCLUSIONS

Our data provide a comprehensive overview on prostein expression in human cancers. Prostein is a highly sensitive prostate cancer marker occurring in > 96% of prostate cancers. Because prostein can also be expressed in various other tumor entities, classifying of a tumor mass as a prostate cancer should not be based on prostein positivity alone.

Identifiants

DOI: 10.1186/s13000-023-01434-5 PMID: 38218896

pubmed: 38218896

doi: 10.1186/s13000-023-01434-5

pii: 10.1186/s13000-023-01434-5

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Xu J, et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res. 2001;61(4):1563–8.

pubmed: 11245466

Bartolke R, et al. Proton-associated sucrose transport of mammalian solute carrier family 45: an analysis in Saccharomyces cerevisiae. Biochem J. 2014;464(2):193–201.

doi: 10.1042/BJ20140572 pubmed: 25164149

Kalos M, et al. Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate. 2004;60(3):246–56.

doi: 10.1002/pros.20043 pubmed: 15176054

Hernandez-Llodra S, et al. ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: strong association of the triple hit phenotype with an aggressive pathway of Prostate cancer progression. Oncotarget. 2017;8(43):74106–18.

doi: 10.18632/oncotarget.18266 pubmed: 29088771 pmcid: 5650326

Esgueva R, et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol. 2010;23(4):539–46.

doi: 10.1038/modpathol.2009.193 pubmed: 20118910 pmcid: 2848699

Lin B, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 1999;59(17):4180–4.

pubmed: 10485450

Shin D, et al. miR-32 and its target SLC45A3 regulate the lipid metabolism of oligodendrocytes and myelin. Neuroscience. 2012;213:29–37.

doi: 10.1016/j.neuroscience.2012.03.054 pubmed: 22521588

Seipel AH, et al. Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study. APMIS. 2016;124(4):263–70.

doi: 10.1111/apm.12504 pubmed: 26778368

Queisser A, et al. Comparison of different prostatic markers in lymph node and distant metastases of Prostate cancer. Mod Pathol. 2015;28(1):138–45.

doi: 10.1038/modpathol.2014.77 pubmed: 24925052

Sheridan T, et al. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol. 2007;31(9):1351–5.

doi: 10.1097/PAS.0b013e3180536678 pubmed: 17721190

Garudadri G, et al. Diagnostic utility of immunohistochemical marker prostein for evaluation of primary and metastatic prostatic carcinomas. Indian J Pathol Microbiol. 2020;63(Supplement):S18–24.

pubmed: 32108621

Mochizuki K, et al. Diagnostic utility of prostein, uroplakin II and SATB2 for diagnosing carcinoma of unknown primary origin: a systematic immunohistochemical profiling. Anticancer Res. 2018;38(8):4759–66.

doi: 10.21873/anticanres.12784 pubmed: 30061246

Osunkoya AO, Netto GJ, Epstein JI. Colorectal adenocarcinoma involving the prostate: report of 9 cases. Hum Pathol. 2007;38(12):1836–41.

doi: 10.1016/j.humpath.2007.04.021 pubmed: 17868775

Srinivasan M, Parwani AV. Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma. Diagn Pathol. 2011;6:67.

doi: 10.1186/1746-1596-6-67 pubmed: 21777423 pmcid: 3163513

Arnesen C, et al. NKX3.1 and Prostein expression in testicular tissue and sex cord-stromal tumors. Am J Surg Pathol. 2020;44(1):61–7.

doi: 10.1097/PAS.0000000000001367 pubmed: 31498176

Chuang AY, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31(8):1246–55.

doi: 10.1097/PAS.0b013e31802f5d33 pubmed: 17667550

Lane Z, et al. Prostatic adenocarcinoma in colorectal biopsy: clinical and pathologic features. Hum Pathol. 2008;39(4):543–9.

doi: 10.1016/j.humpath.2007.08.011 pubmed: 18234278

Xiao GQ, et al. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma. Prostate. 2021;81(8):469–77.

doi: 10.1002/pros.24127 pubmed: 33848377

Kusumi T, et al. Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy. Pathol Int. 2008;58(11):687–94.

doi: 10.1111/j.1440-1827.2008.02294.x pubmed: 18844933

Bonk S, et al. Prognostic and diagnostic role of PSA immunohistochemistry: a tissue microarray study on 21,000 normal and cancerous tissues. Oncotarget. 2019;10(52):5439–53.

doi: 10.18632/oncotarget.27145 pubmed: 31534629 pmcid: 6739211

Tribian LS, et al. Diagnostic role and prognostic impact of PSAP immunohistochemistry: a tissue microarray study on 31,358 Cancer tissues. Diagnostics (Basel). 2023;13(20):3242.

doi: 10.3390/diagnostics13203242 pubmed: 37892063

Thul PJ, et al. A subcellular map of the human proteome. Science. 2017;356(6340):eaal3321.

doi: 10.1126/science.aal3321 pubmed: 28495876

Consortium GT. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45(6):580–5.

doi: 10.1038/ng.2653

Lizio M, et al. Update of the FANTOM web resource: expansion to provide additional transcriptome atlases. Nucleic Acids Res. 2019;47(D1):D752-758.

doi: 10.1093/nar/gky1099 pubmed: 30407557

Lizio M, et al. Gateways to the FANTOM5 promoter level mammalian expression atlas. Genome Biol. 2015;16(1):22.

doi: 10.1186/s13059-014-0560-6 pubmed: 25723102 pmcid: 4310165